7 Part 3: UNDERSTANDING TARGETED DELIVERY SYSTEMS 15 Nanopharmaceuticals: An Approach for Effective Management of Breast Cancer List of Abbreviations 15.1 Introduction 15.2 Stages of Breast Cancer 15.3 Main Types of Breast Cancer 15.4 Drawbacks in Conventional Treatment 15.5 Nanoparticulate Approach for Effective Management of Breast Cancer 15.6 Systematic Drug Delivery System Approaches 15.7 Nanoparticles Targeted Drug Delivery 15.8 Various Ligands used for Targeting Cancer Cells 15.9 New Innovative Pharmaceutical Entities and Targeting Moieties 15.10 Future of Cancer Treatment in Nanotechnology 15.11 Conclusion References 16 Vaginal Nano-Based Drug Delivery System List of Abbreviations 16.1 Introduction 16.2 Vaginal Anatomy Physiology and Diseases of Vagina 16.3 Advantages of Vaginal Drug Delivery 16.4 Drawbacks of Conventional Vaginal Formulation 16.5 Need of Nanocarriers for Vaginal Delivery 16.6 Different Types of Nanoparticles for Vaginal Therapy 16.7 Vaginal Patents 16.8 Nanotoxicity: Future Prospective 16.9 Conclusion References 17 Recent Advances in Polymer-Modified Liposomes for Cancer Treatment List of Abbreviations 17.1 Introduction 17.2 Liposomes 17.3 Future Challenges Associated With Cancer Therapy 17.4 Conclusion References 18 Role of Nanomedicines in Neglected Tropical Diseases List of Abbreviations 18.1 Introduction 18.2 Diseases 18.3 Conclusion Acknowledgement References
8 Part 4: OVERVIEW OF REGULATORY AFFAIRS 19 Current Framework, Ethical Consideration and Future Challenges of Regulatory Approach for Nano-Based Products List of Abbreviations 19.1 Introduction 19.2 Issues in Aspect of Regulation of Drug Delivery System 19.3 Regulation of Nano-Based Products in Global Realms of the World 19.4 Regulatory Challenges and Solutions in DDS Development 19.5 Regulatory Education and its Involvement in Pharmaceutical Industry for the Development of Novel Drug Delivery Systems 19.6 Current Framework and Future Challenges 19.7 Conclusion References
9 Index
List of Illustrations
1 Chapter 1Figure 1.1 Types of liposomes. (a) Unilamellar vesicle, (b) multilamellar vesicl...Figure 1.2 A graphical representation of solid lipid nanoparticle.